PMC:7346000 / 11353-11931 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"338","span":{"begin":287,"end":295},"obj":"Species"},{"id":"339","span":{"begin":467,"end":475},"obj":"Species"},{"id":"340","span":{"begin":547,"end":555},"obj":"Species"},{"id":"342","span":{"begin":97,"end":103},"obj":"Disease"},{"id":"343","span":{"begin":104,"end":130},"obj":"Disease"},{"id":"344","span":{"begin":175,"end":182},"obj":"Disease"},{"id":"345","span":{"begin":187,"end":206},"obj":"Disease"},{"id":"346","span":{"begin":326,"end":338},"obj":"Disease"},{"id":"347","span":{"begin":561,"end":569},"obj":"Disease"}],"attributes":[{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"Tax:9606"},{"id":"A339","pred":"tao:has_database_id","subj":"339","obj":"Tax:9606"},{"id":"A340","pred":"tao:has_database_id","subj":"340","obj":"Tax:9606"},{"id":"A342","pred":"tao:has_database_id","subj":"342","obj":"MESH:D009369"},{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"MESH:D000072742"},{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"MESH:D004342"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:D003141"},{"id":"A346","pred":"tao:has_database_id","subj":"346","obj":"MESH:D009369"},{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T119","span":{"begin":97,"end":103},"obj":"Disease"},{"id":"T120","span":{"begin":175,"end":182},"obj":"Disease"},{"id":"T121","span":{"begin":187,"end":197},"obj":"Disease"},{"id":"T122","span":{"begin":207,"end":214},"obj":"Disease"},{"id":"T123","span":{"begin":561,"end":569},"obj":"Disease"}],"attributes":[{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0005271"},{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0002041"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T81","span":{"begin":54,"end":66},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T82","span":{"begin":256,"end":261},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T61","span":{"begin":234,"end":237},"obj":"Chemical"},{"id":"T63","span":{"begin":369,"end":372},"obj":"Chemical"}],"attributes":[{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_64220"},{"id":"A62","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_64243"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A64","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T20","span":{"begin":97,"end":103},"obj":"Phenotype"},{"id":"T21","span":{"begin":104,"end":130},"obj":"Phenotype"},{"id":"T22","span":{"begin":175,"end":182},"obj":"Phenotype"},{"id":"T23","span":{"begin":369,"end":372},"obj":"Phenotype"}],"attributes":[{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0020101"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0012393"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T62","span":{"begin":0,"end":578},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}

{"project":"2_test","denotations":[{"id":"32599813-31802125-60095095","span":{"begin":252,"end":254},"obj":"31802125"},{"id":"32599813-30565352-60095096","span":{"begin":571,"end":573},"obj":"30565352"},{"id":"32599813-22517788-60095097","span":{"begin":574,"end":576},"obj":"22517788"}],"text":"Despite these important differences, revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions [43] focus primarily on neutropenic patients with underlying hematological malignancies and “typical” presentation of IPA and have been shown to have limited applicability and inferior performance in non-neutropenic patients who frequently do not fulfil radiological and host criteria, including patients with COVID-19 [41,44]."}